The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2022 | Quadruplet induction therapy as a new standard of care in multiple myeloma
Enrique Ocio
• 9 Jun 2022
Enrique Ocio, MD, PhD, Marqués de Valdecilla University Hospital, Santander, Spain, comments on the tolerability and efficacy of quadruplet induction regimens in transplant-eligible and transplant-ineligible patients with multiple myeloma. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
